US$ 25.62
glp 1 agonisté Léčba cukrovky 2. typu analogy GLP-1 The GLP-1 Agonists and Obesity:
Description
doi: 10.1080/14656566.2019.1571040 122 GenoveseSMannucciECerielloA

Guidance on research versus pharmaceutical peptides clarifies risks and considerations

[DOI] [PubMed] [Google Scholar] 58.Witko-Sarsat V., Friedlander M., Capeillre-Blandin C., et al

The move greatly broadens access for existing players like Lilly and Novo, but could cool incentives for new competitors and push back obesity drug innovation

doi:10.1172/JCI97943

Rahbari, N
